Skip to main content

Table 4 Estimates from a hierarchical Bayesian model of the sustained virological response rates at 4 weeks (SVR4) and at 12 weeks (SVR12) after completing therapy with daclatasvir and sofosbuvir, with or without ribavirin

From: The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease

Estimate SVR4 SVR12
  As-treated Intent-to-treat As-treated Intent-to-treat
Country % 95% CI % 95% CI % 95% CI % 95% CI
Austria 97 87–100 92 81–99 98 89–100 88 75–96
Denmark 93 77–100 88 73–97 98 89–100 87 73–95
Spain 98 95–100 92 95–100 98 94–100 89 83–94
Sweden 96 79–100 90 73–100 97 85–100 87 72–96
Switzerland 82 56–97 82 59–94 82 57–97 84 64–93
UK 96 80–100 82 52–95 97 83–100 82 56–93
Overall 96 86–100 89 76–96 97 89–100 87 75–94
  1. These estimates apply to patients with genotype 1 hepatitis C, previously treated and now with decompensated cirrhosis